Ad hoc:Agennix AG:Ad hoc: Agennix AG Raises ¤ 9.8 .

Martinsried/Munich (Germany), Princeton, NJ and Houston, TX, March 21, 2010 -
Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company has
raised approximately ¤ 9.8 million (approximately $13 million) in a private
placement with existing shareholders. Agennix sold 1,870,523 shares at a price
of ¤ 5.22 per share. The newly issued shares, which were issued from authorized
capital, represent 9.1% of Agennix's total shares outstanding after the
transaction.

The Management Board and Supervisory Board of Agennix approved the capital
increase at their meetings on March 21, 2010.  The Company has resolved to
increase its total share capital from ¤ 18,707,432 by an amount of ¤ 1,870,523
to a total share capital of ¤ 20,577,955 by issuing 1,870,523 new ordinary
bearer shares. The pre-emptive rights of the existing shareholders have been
excluded.

Agennix intends to use the proceeds of this private placement to continue the
development of talactoferrin and to fund ongoing operations.

END OF AD HOC ANNOUNCEMENT
About Agennix

Agennix AG is a publicly traded biopharmaceutical company that is developing
novel therapies in areas of major unmet medical need to improve the length and
quality of life of seriously ill patients. The Company's most advanced program
is talactoferrin, an oral targeted therapy that has demonstrated activity in
randomized, double-blind, placebo-controlled Phase 2 studies in non-small cell
lung cancer as well as in severe sepsis. Talactoferrin is currently in Phase 3
clinical trials in non-small cell lung cancer. Other clinical development
programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1
testing; the oral platinum-based compound satraplatin; and a topical gel form of
talactoferrin for diabetic foot ulcers. Agennix's registered seat is in
Heidelberg, Germany. The Company has three sites of operation:
Martinsried/Munich, Germany; Princeton, New Jersey and Houston, Texas. For
additional information, please visit the Agennix Web site at www.agennix.com.

The shares have not been, and will not be, registered under the U.S. Securities
Act of 1933, as amended, or any state securities laws in the U.S., and unless so
registered, may not be offered or sold in the United States absent registration
or an applicable exemption from registration requirements. This announcement
does not constitute an offer to sell or the solicitation of an offer to buy, nor
shall there be any sale of shares in any state in the U.S. in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state.

This ad hoc announcement contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. There can be no guarantee that the Company will procure additional
funding that is sufficient to continue its operations. Actual results could
differ materially depending on a number of factors, and we caution investors not
to place undue reliance on the forward-looking statements contained in this ad
hoc announcement. Forward-looking statements speak only as of the date on which
they are made and Agennix undertakes no obligation to update these
forward-looking statements, even if new information becomes available in the
future.

For further information, please contact:

Agennix
AG
Investor Relations & Corporate Communications
Phone: +49 (0)89
8565 2693
ir@agennix.com


In the U.S.: Laurie
Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884

laurie.doyle@agennix.com


Additional media contacts for Europe:
MC Services
AG
Phone: +49 (0) 89 210 228 0

Raimund
Gabriel
raimund.gabriel@mc-services.eu


Hilda
Juhasz
hilda.juhasz@mc-services.eu



Additional investor contact for Europe:
Trout International
LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com








[HUG#1395903]



--- End of Message ---

Agennix AG
Fraunhoferstr. 20 Martinsried Germany

ISIN: DE000A1A6XX4;
Listed: Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;